

IN THE CLAIMS

1. (original) An orally deliverable pharmaceutical composition comprising an effective amount of 2'-deoxy-2'-(fluoromethylene)cytidine for treating a neoplastic disease or viral disease in a mammal wherein said composition is encapsulated in a material which is selected to be dissolution resistant at a pH of about 4 to 5 or less and to readily dissolve at a pH of greater than about 4 to 5.

2. (original) The orally deliverable pharmaceutical composition according to Claim 1 further comprising a pharmaceutically acceptable excipient or excipients.

3. (original) The orally deliverable pharmaceutical composition according to Claim 2 wherein the pharmaceutically acceptable excipient or excipients comprise only the encapsulation material.

4. (original) The orally deliverable pharmaceutical composition according to Claim 2 wherein a separate pharmaceutically acceptable excipient or excipients is/are included in the encapsulation material.

5. (currently amended) The orally deliverable pharmaceutical composition according to ~~any of Claims 1, 2, 3 or 4~~ claim 1 wherein the encapsulation material is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, poly(vinyl acetate phthalate), hydroxypropyl methylcellulose acetate succinates, poly(meth)acrylates and cellulose acetate phthalate/diethylphthalate.

6. (currently amended) The orally deliverable pharmaceutical composition according to Claim 5 wherein the encapsulation material is selected from the group consisting of [[a]]

copolymers of methacrylic acid and acrylic acid esters and copolymers of methacrylic acid and methacrylic acid esters.

7. (currently amended) The orally deliverable pharmaceutical composition according to Claim [[1]] 2 wherein the composition comprises from about 50 to about 99.5 weight percent of the pharmaceutically acceptable excipient(s) and from about 0.5 to about 50 weight percent of 2'-deoxy-2'-(fluoromethylene)cytidine.

8. (original) A method for enhancing the oral bioavailability of 2'-deoxy-2'-(fluoromethylene)cytidine when orally delivered to a mammal which method comprises:

(a) encapsulating 2'-deoxy-2'-(fluoromethylene)cytidine in a pharmaceutically acceptable material which is selected to be dissolution resistant at a pH of 4 to 5 or less and to readily dissolve at a pH of greater than 4 to 5; and

(b) orally delivering the product prepared in (a) above to said mammal.

9. (new) A method of treating a neoplastic disease comprising administering to a mammal in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1.

10. (new) The method of claim 9 further comprising administering radiation to the mammal.

11. (new) The method of claim 9 further comprising administering a chemotherapeutic agent to the mammal.

12. (new) A method of treating a viral disease comprising administering to a mammal in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1.

13. (new) The method of claim 12 further comprising administering a second drug to the mammal.